In our last analysis , following a stock derating, we decided to reinstate a buy rating on Stevanato Group (NYSE: STVN ). For our new readers, the company is a leading player in drug containment and delivery. Life sciences and biopharmaceutical players useBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-40618 Stevanato Group S.p.A. | | Page | | --- | --- | | Introduction | i | | Cautionary Statements Regarding Forward-Looking Statements | ii | | Unaudited Interim Condensed Consolidated Financial Statements | 1 | | Management's Discussion and Analysis of Financia ...

Stevanato Group S.p.A. (NYSE:STVN) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Lisa Miles - Senior Vice President & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Larry Solow - CJS Securities Patrick Donnelly - Citi Jacob Johnson - Stephens Dave Windley - Jefferies Paul Knight - KeyBanc Capital Markets Dan Leonard - UBS Curtis Moiles - BNP Paribas E ...

Stevanato Group Q3 2024 Financial Results November 5, 2024 Safe Harbor Statement 2 Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. ("we", "our", "us", "Stevanato Group" or the "Company") and which involve known and unknown risks, uncertainties and assumptions because they relate to events and depend on circumstances that will occur in th ...

Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this maker of glass vials for COVID-19 vaccines would post earnings of $0.10 per share when it actually produced earnings of $0.10, delivering no surprise.Over the last four quarters, the company has not been able to surpass consensus EPS estimates. ...

Stevanato Group S.p.A. (NYSE:STVN) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Lisa Miles - IR Franco Stevanato - Executive Chairman and CEO Marco Dal Lago - CFO Conference Call Participants Jacob Johnson - Stephens Paul Knight - KeyBanc Matt Larew - William Blair John Kim - Bank of America Patrick Donnelly - Citi David Windley - Jefferies Larry Solow - CJS Securities Dan Leonard - UBS Curtis Moiles - BNP Paribas Exane Operator Good afternoon. This is the Chorus call conf ...

Stevanato Group (STVN) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this maker of glass vials for COVID-19 vaccines would post earnings of $0.12 per share when it actually produced earnings of $0.09, delivering a surprise of -25%. Over the last four quarters, the company has not been able to surpass consensus EPS e ...

The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. Stevanato Group (STVN) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term ...

Maskot/DigitalVision via Getty Images In our last assessment, we decided to lower Stevanato Group's (NYSE:STVN) rating due to 'Destocking And Valuation Risk.' As a reminder, having checked Stevanato's peers' lower sales growth estimates in 2024 and anticipating a decline in EBITDA and net profit due to start-up costs and an unfavorable exchange rate effect, the company's valuation was full in our view. No sooner said than done. Following the FY 2023 analysis, Stevanato's share price dropped by almost 30%. T ...

Marco Dal Lago Yes. Our guidance is assuming now a gap compared to prior guidance of approximately €55 million. About the gap, about 65% of the gap is related to vials with more pronounced gap on EZ-fill vials in this period of time. The remaining 25% is associated to the large order we were mentioning and 10% is related to Engineering. So this is the breakdown of the delta we assume today based on, again, the visibility we have, and review guidance for those three reasons. Lisa Miles And Sam, I apologize. ...